A quick reference guide illustrating recommended practices for managing hepatitis C infections with links to more detailed discussion of the research and evidence base.
Management of Hepatitis C
Management of chronic HCV
The following groups should be tested for HCV:
In children born to women infected with HCV, an HCV antibody test should be performed at 12 months of age or thereafter.
Anyone with one of the following criteria should be offered an HCV test:
Patients with acute HCV infection should be referred to specialist care immediately.
Individuals, including injecting drug users, diagnosed with chronic HCV should be offered integrated multidisciplinary care.
Patients with acute HCV infection which does not resolve spontaneously should start treatment between three and six months after diagnosis and receive IFN therapy for 24 weeks irrespective of genotype.
A combination of pegylated IFN and ribavirin is the treatment of choice for patients with hepatitis C.
Knowledge of HCV RNA positive status should not influence obstetric management of pregnant women or standard advice regarding breast feeding.
There should be early consideration of antiviral therapy for patients with HCV with HIV co-infection.
Patients with CHC and HIV should receive treatment for 48 weeks irrespective of genotype.
In patients with HCV genotype 1 infection and HIV, the lack of an EVR at week 12 predicts absence of an SVR, and treatment can be stopped.
The following patient groups should all be considered for treatment with pegylated IFN and ribavirin:
patients with mild CHC
patients with chronic hepatitis C and normal ALT
patients with chronic hepatitis B and C co-infection
patients with CHC who are on a drug treatment programme
patients with stable mental health problems should not be excluded from treatment for CHC. Psychiatric symptoms should be monitored prior to and throughout IFN treatment
children with evidence of moderate or severe liver disease.